Our studies found that the NDV AMHA1 strain inhibits the glycolysis pathway in breast cancer cells by interfering with glycolysis enzymes such as hexokinase and GAPDH (Al-Shammari et al., 2019; Al-Ziaydi et al., 2020a). Here, GAPDH is linked to breast carcinoma.